RAP-219 Phase 2 trial results in bipolar mania are positive
Rapport Therapeutics reported positive Phase 2 trial results for RAP-219 in bipolar mania, and management expects to initiate two Phase 3 trials in 2H 2027.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed